Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa

Strong Phase 2 data, but key details are missing and risks remain high for investors.

Risk flags

• ●Operational risk is high: The company must now design, fund, and execute a large, complex Phase 3 trial, which is a major step up in scale and complexity from Phase 2. Many drugs that succeed in Phase 2 fail in Phase 3 due to differences in patient populations, endpoints, or unforeseen safety issues.
• ●Financial risk is opaque: No financial data, cash runway, or funding plans are disclosed. Investors have no visibility into whether Avalo has the resources to complete a Phase 3 program or will need to raise dilutive capital.
• ●Disclosure risk is material: The announcement omits key numerical data for secondary endpoints and safety outcomes, making it impossible to independently verify the breadth of the efficacy or the true safety profile. This pattern of selective disclosure is a red flag for transparency.
• ●Pattern-based risk: The company uses superlative language (“highest absolute improvement,” “well tolerated”) without providing comparative benchmarks or quantitative safety data. This suggests a tendency to overstate positives and underreport negatives.
• ●Timeline/execution risk: The only forward-looking milestone is the plan to advance to Phase 3, which is years away from delivering value. Most claims are forward-looking, and the path to commercialization is long and uncertain.
• ●Geographic and regulatory risk: The trial was conducted across multiple geographies (United States, Australia, Ukraine), which can introduce variability in patient populations, regulatory standards, and operational execution.
• ●Capital intensity risk: The mention of “availability of funding sufficient for our operating expenses and capital expenditure requirements” signals that significant new capital will be needed, but no details are provided. Phase 3 trials are expensive, and the lack of a disclosed funding plan increases the risk of future dilution or financial distress.
• ●Leadership risk: While the CEO and a prominent academic are named, there is no mention of external validation, partnership, or institutional investment, which could otherwise de-risk the program or provide non-dilutive funding.

Bottom line

For investors, this announcement means Avalo Therapeutics has delivered a clear, statistically significant efficacy signal for abdakibart in a Phase 2 trial for hidradenitis suppurativa, but the story is far from complete. The topline data for the primary endpoint is credible and positive, but the lack of numerical detail for secondary endpoints and safety outcomes is a major limitation. No financial data is disclosed, so investors cannot assess the company’s cash position, burn rate, or ability to fund the next phase of development. The involvement of named executives and a respected academic lends some credibility, but there is no evidence of external institutional validation or partnership, which would be critical for de-risking a capital-intensive Phase 3 program. To change this assessment, Avalo would need to provide full numerical results for all endpoints, detailed safety data, and a transparent financial update including cash runway and funding plans. Key metrics to watch in the next reporting period include full Phase 2 data (especially secondary endpoints and safety), any partnership or licensing deals, and explicit disclosure of financial runway and capital needs. At this stage, the signal is worth monitoring but not acting on, as the risks and unknowns outweigh the single positive efficacy result. The most important takeaway: while the Phase 2 result is encouraging, the lack of transparency and looming capital and execution risks mean this is not yet a de-risked investment opportunity.

Announcement summary

Avalo Therapeutics, Inc. (NASDAQ:AVTX) announced positive topline results from its Phase 2 LOTUS trial evaluating abdakibart in adults with moderate to severe hidradenitis suppurativa (HS). The trial met its primary endpoint of HiSCR75 at Week 16 for both the 150 mg and 300 mg doses, with response rates of 42.2% (p=0.018) and 42.9% (p=0.015), respectively, which are the highest rates observed in a trial of this size or larger. Statistically significant benefits were also demonstrated on key secondary endpoints, and abdakibart was well tolerated with a favorable safety profile. Based on these results, Avalo plans to advance abdakibart into a registrational phase 3 program. The LOTUS trial enrolled 253 adults and was conducted over a 16-week treatment period.

Disagree with this article?